Minimal residual disease-based effect and long-term outcome of first-line dasatinib combined with chemotherapy for adult Philadelphia chromosome-positive acute lymphoblastic leukemia

First-line incorporation of dasatinib into chemotherapy is effective for achieving a good quality molecular response and durable disease-free survival in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia. Quantitatively monitoring minimal residual disease kinetics is important to identify a subgroup of patients at high risk of treatment failure.

from Cancer via ola Kala on Inoreader http://ift.tt/21ij6y7
via IFTTT